Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Differences in diet between the 19th and 21st centuries: could they lead to insu...
Información de la revista
Vol. 58. Núm. 5.
Páginas 252-254 (Mayo 2011)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 58. Núm. 5.
Páginas 252-254 (Mayo 2011)
Carta al Editor
Acceso a texto completo
Differences in diet between the 19th and 21st centuries: could they lead to insulin and leptin resistance and inflammation?
Diferencias alimentarias entre los siglos xix y xxi: ¿podrían conducir a la inflamación y resistencia a la insulina y a la leptina?
Visitas
7576
Gustavo Duarte Pimentela,
Autor para correspondencia
, José Cesar Rosab, Fábio Santos de Lirab
a Department of Internal Medicine, FCM, State University of Campinas (UNICAMP), Campinas, SP-Brazil
b Department of Physiology of Nutrition, Federal University of Sao Paulo (UNIFESP), São Paulo, SP-Brazil
Contenido relaccionado
Gustavo Duarte Pimentel, José Cesar Rosa, Fábio Santos de Lira
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (1)
Texto completo

There is a growing perception that profound environmental changes in areas such as diet and lifestyle that began with introduction of agriculture and taming of animals about 10,000 years ago actually occurred very recently on an evolutionary time scale. Evolution from the paleolithic diet to our current modern intake pattern also resulted in several changes in feeding behavior, including increased consumption of processed foods rich in sodium and hydrogenated fats and low in fiber.1–3 Changes in several food parameters, such as increased calorie intake (mainly of foods rich in saturated/trans fatty acids) and serving sizes, including introduction of “super size” meals, are known to play roles in the advent of non-communicable chronic diseases.4,5

The interest in the study of lipids has increased since the 19th century. Vogel, in 1847, was the first researcher to detect the presence of cholesterol in atherosclerotic plaques. A century later, Bang & Dyerberg6 noted that Eskimos had a low incidence of cardiovascular diseases despite their high-fat diet, and suggested for the first time that omega-3 fatty acids are responsible for inhibiting obesity-related diseases.

After World War II and industrialization, fast-food chains began providing meals rich in saturated/trans fatty acids, which may be responsible for the high prevalence of obesity.7 Thus, in 1994, after the discovery of leptin,8 several studies demonstrated that high-fat diets lead to obesity and induce inflammation in peripheral tissues and hypothalamus, promoting insulin and leptin resistance.9,10 These results may partially be explained by accumulation of intracellular fatty acids (e.g. acyl-CoA); free fatty acids (FFAs) released by adipocytes via lipolysis may induce inflammatory changes and lead to impaired insulin and leptin signaling.11 Recently, Wang et al.12 demonstrated that lipoprotein lipase (LPL), a serine hydrolase that releases FFAs from circulating triacylglycerol-rich lipoproteins, might contribute to FFA-mediated signalling in the central nervous system. The authors found that neuron-specific homozygous mutant (NEXLPL-/-) mice are hyperphagic and become obese by 16 weeks of age (fig. 1).

Figure 1.

Obesity and saturated/trans fatty acids-rich diets leads to insulin/leptin resistance and inflammation in several tissues.

IRS-1 and 2: insulin receptor substrate 1 and 2, IKK-β: inhibitor of nuclear factor-κB kinase, p85: regulatory subunit of PI3-K, p110: catalytic subunit of PI3-K, PI3-K: phosphatidylinositol 3-kinase, PIP: phosphatidylinositol protein, PIP2: phosphatidylinositol-4,5-bisphosphate, PIP3: phosphatidylinositol-3,4,5-triphosphate, PDK1: 3-phosphoinositide–dependent protein kinase, Akt/PKB: protein kinase B, PKC: protein kinase C, GSK-3: glycogen synthase kinase-3, GLUT-2,4: glucose transporter 2,4, MyD88: myeloid differentiation factor 88, p50: p50 subunit of NFκB, p65: p65 subunit of NFκB, pIKBα: phospho-inhibitory subunit of NF-κBα, pIKKβ: phosphorylated IKKβ, NFκB: nuclear factor kappa B, IL-6: interleukin 6, IL-8: interleukin 8, IL-1β: interleukin-1β, TNF-α: tumor necrosis factor alpha, SOCS3: suppressor of cytokine signaling-3, TLR4: toll-like receptors, LPL: lipoprotein lipase, LPS: lipopolysaccharides, JAK: Janus kinase, STAT3: signal transducer and activator of transcription 3.

(0,82MB).

These increased acyl-CoA/FFA levels activate the serine/threonine kinase protein kinase C (PKC), which can phosphorylate insulin receptor substrates (IRSs) and activate toll-like receptors (TLR2/4), activating the nuclear factor-κB kinase complex (IKK-β) and nuclear factor kappa B (NF-κB P50/p65), and increasing secretion of inflammatory cytokines leading to insulin and leptin resistance. Moreover, saturated/trans fatty acids and enteric lipopolysaccharides (LPS) may act as direct ligands for TLR2/4,9,11,13,14 activating PKC and resulting in insulin resistance (fig. 1). However, other signaling pathways that are involved in insulin resistance can also be regulated by saturated/trans fatty acids through TLR4; these include the mitogen-activated protein kinases (MAPKs), c-Jun amino-terminal kinase (JNK), endoplasmic reticulum (ER) stress, the unfolded protein response (UPR) and ceramide pathways, as well as inhibition of peroxisome proliferator-activated receptor (PPAR) gamma and adiponectin signaling.10,14–16 Consumption of saturated fatty acid-rich diets blunts leptin anorexigenic signaling in hypothalamus through an inflammation-dependent mechanism, probably by activation of TLR4 and myeloid differentiation factor 88 (MyD88)17,18 (fig. 1).

Another potential cause for obesity-associated diseases is activation of protein-tyrosine phosphatase (PTP)-1B, a key enzyme involved in regulation of reversible tyrosine phosphorylation. PTP-1B may be activated by saturated fatty acids and inflammation and, once activated, causes inactivation of insulin receptor by removing phosphates from the active insulin receptor and its substrates.19,20 Interestingly, PTP-1B may also dephosphorylate Janus kinase/signal transducer and activator of transcription (JAK/STAT3), decreasing leptin effects and causing leptin resistance.20–22 Moreover, studies show that stimulation of the mammalian target of the rapamycin (mTOR/p70S6K) pathway is associated with IRS-1/2 serine phosphorylation and impaired Akt activation by insulin23,24 (fig. 1).

In summary, it is evident that changes in diet and advent of industrialization, with the rise of fast food chains and sedentary lifestyles, have increased the prevalence of low-grade inflammatory conditions such as cardiovascular diseases, metabolic syndrome, diabetes, and obesity. However, subjects who have not made these dietary changes do not develop metabolic abnormalities. In addition, healthy eating, with low saturated/trans fatty acid or high polyunsaturated fatty acid levels, may partially reverse these diseases. Thus, future studies should be performed to evaluate the consequences of this change in diet; such studies should particularly focus on as yet uncharacterized aspects of fat intake and on anti-inflammatory therapies that may be used for the treatment of obesity-related diseases.

References
[1]
L. Frassetto, R.C. Morris Jr., D.E. Sellmeyer, K. Todd, A. Sebastian.
Diet, evolution and aging-the pathophysiologic effects of the post-agricultural inversion of the potassium-to-sodium and base-to-chloride ratios in human diets.
Eur J Nut, 40 (2001), pp. 200-213
[2]
L. Cordain, S.B. Eaton, A. Sebastian, N. Mann, S. Lindeberg, B.A. Waikins, et al.
Origins and evolution of the Western diet: health implications for the 21st century.
Am J Clin Nutr, 81 (2005), pp. 341-354
[3]
S. Jew, S.S. AbuMweis, P.J.H. Jones.
Evolution of the human diet: Linking our ancestral diet to modern functional foods as a means of chronic disease prevention.
J Medic Food, 12 (2009), pp. 925-934
[4]
G.A. Bray, B.M. Popkin.
Dietary fat intake does affect obesity!.
Am J Clin Nutr, 68 (1998), pp. 1157-1173
[5]
K.F. Hulshof, M.A. van Erp-Baart, M. Anttolainen, W. Becker, S.M. Church, C. Couet, et al.
Intake of fatty acids in Western Europe with emphasis on trans fatty acids: the TRANSFAIR Study.
Eur J Clin Nutr, 53 (1999), pp. 143-157
[6]
H.O. Bang, J. Dyerberg.
Plasma lipids and lipoproteins in Greenlandic west coast Eskimos.
Acta Med Scand, 192 (1972), pp. 85-94
[7]
A. Astrup, J. Dyerberg, M. Selleck, S. Stender.
Nutrition transition and its relationship to the development of obesity and related chronic diseases.
Obes Rev, 9 (2008), pp. S48-52
[8]
Y. Zhang, R. Proença, M. Maffei, M. Baroni, L. Leopold, J.M. Friedman.
Positional cloning of the mouse obese gene and its human homologue.
Nature, 372 (1994), pp. 425-432
[9]
C.Z. Larter, G.C. Farrell.
Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?.
J Hepatology, 44 (2006), pp. 253-261
[10]
E.R. Ropelle, M.B. Flores, D.E. Cintra, G.Z. Rocha, J.R. Pauli, J. Morari, et al.
IL-6 and IL-10 anti-inflammatory activity links exercise to hypothalamic insulin and leptin sensitivity through IKKbeta and ER stress inhibition.
Plos Biology, 8 (2010), pp. e1000465
[11]
J.Y. Lee, K.H. Sohn, S.H. Rhee, D. Hwang.
Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4.
J Biol Chem, 276 (2001), pp. 16683-16689
[12]
H. Wang, G. Astarita, M.D. Taussig, K.G. Bharadwaj, N.V. DiPatrizio, K.A. Nave, et al.
Deficiency of lipoprotein lipase in neurons modifies the regulation of energy balance and leads to obesity.
Cell Metab, 13 (2011), pp. 105-113
[13]
D.M. Tsukumo, B.M. Carvalho, M.A. Carvalho-Filho, M.J.A. Saad.
Translational research into gut microbiota: new horizons in obesity treatment.
Arq Bras Endocr Metab, 53 (2009), pp. 139-144
[14]
G.D. Pimentel, F.S. Lira, J.C. Rosa, J.L. Oliveira, A.C. Losinska-Hachul, G.I. Souza, et al.
Intake of trans fatty acids during gestation and lactation leads to hypothalamic inflammation via TLR4/NFkBp65 signaling in adult offspring.
J Nutr Biochem, (2011 [In press]),
[15]
J.M. Olefsky, A.R. Saltiel.
PPAR gamma and the treatment of insulin resistance.
Trends Endocrinol Metab, 11 (2000), pp. 362-368
[16]
J.K. Kim.
Fat uses a TOLL-road to connect inflammation and diabetes.
Cell Metab, 4 (2006), pp. 417-419
[17]
J.C. Moraes, A. Coope, J. Morari, D.E. Cintra, E.A. Roman, J.R. Pauli, et al.
High-fat diet induces apoptosis of hypothalamic neurons.
[18]
A. Kleinridders, D. Schenten, A.C. Könner, B.F. Belgardt, J. Mauer, T. Okamura, et al.
MyD88 signaling in the CNS is required for development of fatty acid-induced leptin resistance and diet-induced obesity.
Cell Metabol, 10 (2009), pp. 249-259
[19]
E.R. Ropelle, J.R. Pauli, P.O. Prada, C.T. de Souza, P.K. Picardi, M.C. Faria, et al.
Reversal of diet-induced insulin resistance with a single bout of exercise in the rat: the role of PTP1B and IRS-1 serine phosphorylation.
J Physiol, 577 (2006), pp. 997-1007
[20]
J.M. Zabolotny, Y.B. Kim, L.A. Welsh, E.E. Kershaw, B.G. Neel, B.B. Kahn.
Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo.
J Biol Chem, 283 (2008), pp. 14230-14241
[21]
D. Barford, A.J. Flint, N.K. Tonks.
Crystal structure of human protein tyrosine phosphatase 1B.
Science, 263 (1994), pp. 1397-1404
[22]
A. Cheng, N. Uetani, P.D. Simoncic, V.P. Chaubey, A. Lee-Loy, C.J. McGlade, et al.
Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B.
Dev Cell, 2 (2002), pp. 497-503
[23]
H. Ono, A. Pocai, Y. Wang, H. Sakoda, T. Asano, J.M. Backer, et al.
Activation of hypothalamic S6 kinase mediates diet-induced hepatic insulin resistance in rats.
J Clin Investigat, 118 (2008), pp. 2959-2968
[24]
M. Ueno, J.B.C. Carvalheira, R.C. Tambascia, R.M.N. Bezerra, M.E. Amaral, E.M. Carneiro, et al.
Regulation of insulin signalling by hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway.
Diabetologia, 48 (2005), pp. 506-518
Copyright © 2010. SEEN
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos